Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Dermatitis Artefacta : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Alopecia Areata

Anagen Effluvium

Atopic Dermatitis

Bedbug Bites

Contact Dermatitis, Allergic

Contact Dermatitis, Irritant

Delusions of Parasitosis

Friction Blisters

Impetigo

Insect Bites

Neurotic Excoriations

Onycholysis

Prurigo Nodularis

Pruritus and Systemic Disease

Telogen Effluvium

Trichotillomania




Patient Education
Click here for patient education.



Author: John YM Koo, MD, Vice Chair, Department of Dermatology, University of California San Francisco Medical Center; Professor, Clinical Dermatology, Department of Dermatology, University of California at San Francisco School of Medicine

John YM Koo is a member of the following medical societies: American Academy of Dermatology, American Psychiatric Association, and National Psoriasis Foundation

Coauthor(s): Patricia T Ting, MD, Staff Physician, Department of Medicine, University of Calgary

Editors: Jacek C Szepietowski, MD, PhD, Professor and Vice-Head, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center

Author and Editor Disclosure

Synonyms and related keywords: factitious disorder, Munchhausen's syndrome by proxy, Münchhausen syndrome by proxy, Munchhausen syndrome by proxy, acne excoriee, picker's nodules, picker nodules, psychocutaneous disease, psychosomatic dermatoses, self-injurious behaviors, obsessive-compulsive behavior, attention-seeking behavior, self injury, self-induced excoriations

Background

The skin and nervous system develop adjacent to each other as the ectoderm and neuroectoderm, respectively, in the embryo and remain interconnected throughout life. Dermatitis artefacta is defined as the deliberate and conscious production of self-inflicted skin lesions to satisfy an unconscious psychological or emotional need. These skin lesions serve as powerful, self-expressive, nonverbal messages. Patients often deny responsibility for their creation. Neurotic excoriation is differentiated from dermatitis artefacta by its conscious compulsive nature. Dermatitis artefacta falls under the general category of factitious disorders, which excludes neurotic excoriations, delusional disorders, malingering, and Münchhausen syndrome (except Münchhausen syndrome by proxy).

Psychiatric conditions, in particular depression, anxiety, personality disorders, delusional disorders, and dissociative disorders, are often coexistent in 25-33% of all dermatological conditions. Dermatitis artefacta may occur in persons of any age and commonly manifests within the context of chronic medical and/or dermatological conditions. These self-induced skin lesions may be present continuously, or they may be episodic, occurring during periods of heightened psychosocial stress and/or uncontrolled psychoses. Patients with dermatitis artefacta require both dermatological assessment and psychosocial support.

Pathophysiology

The pathophysiology of dermatitis artefacta is poorly understood. Multifactorial causes include genetics, psychosocial factors, and personal or family history of psychiatric illness. Commonly, a family member is involved in the medical field, and patients tend to be well versed in medical terminology.

Acute episodes often represent a maladaptive response to a psychosocial stressor. Long-standing cases may be secondary to underlying anxiety or depression, emotional deprivation, an unstable body image, or a personality disorder with borderline features. Many patients also have an associated chronic medical or dermatological condition.

Frequency

International

The prevalence in the pediatric population is 1 case in 23,000 persons. It is more common than is typically thought because it is poorly recognized and underreported.

Mortality/Morbidity

Dermatitis artefacta is poorly recognized and underreported. Additionally, many patients are lost to follow-up.

  • Continuous or repeated episodes of self-mutilation may result in disfiguring scars on exposed areas of the body.
  • Approximately 30% of all dermatological conditions are associated with a psychiatric disorder.
  • Suicide is an important consideration in patients with a comorbid psychiatric illness.

Race

No racial or ethnic predisposition has been noted.

Sex

Most patients with dermatitis artefacta are females.

  • In persons younger than 16 years, the female-to-male ratio is 4.7-7:1.
  • In the general population, the female-to-male ratio is 3-20:1.

Age

The highest incidence occurs between late adolescence (age 11-14 y) and early adulthood.



History

  • Patients are usually otherwise healthy and usually do not provide a substantial indicative history, perhaps revealing vague accounts of antecedent events.
  • Patients may report a personal history of chronic dermatoses, including acne, alopecia (ie, alopecia areata, androgenic alopecia), atopic dermatitis, chronic idiopathic urticaria, psoriasis, rosacea, or vitiligo.
  • They may have a personal or family history of psychiatric illness, including anxiety, depression, personality disorder (ie borderline, dependent, obsessive-compulsive), dissociative disorder, body dysmorphic disorder, or posttraumatic stress disorder. Patients typically are also reluctant to seek a consultation with a psychiatrist.
  • They may have a personal history of chronic medical conditions, chronic pain syndromes, or both.
  • Patients may report a history of childhood neglect or abuse, sexual abuse, or psychological trauma.
  • Münchhausen syndrome by proxy (form of dermatitis artefacta) manifests as skin lesions caused by a parent or caregiver (often the mother). It usually occurs with children younger than 5 years.
  • Pertinent information from the history includes the patient's quality of life with regard to health-related issues, his or her perception of the skin condition, the role of a psychosocial stressor, the presence of a lengthy medical file with numerous consultations, an extensive list of previously used medications, and a history of substance abuse. Also inquire about family members or significant others and their reaction to the skin lesions. Anger, frustration, and impatience are commonly reported reactions.

Physical

Dermatitis artefacta is a challenging clinical diagnosis. It is suggested based on findings that include an absence of other dermatoses to explain the lesions and histological findings that are inconsistent with the clinical presentation.

  • The morphology of the skin lesions is variable and bizarre and is typically dependent on the mechanism of injury. Features may include sharp margins adjacent to normal skin, geometric shapes, and linear tracks (ie, secondary to exposure to corrosive liquids).
  • Most often, the lesions are found at sites accessible to the patient. Typical locations include the face (45%), upper extremity (ie, hand and forearm; 24%), lower extremities (31%), trunk (24%), upper arm (7%), and scalp (7%). Lesions are usually within reach of the dominant hand.
  • The appearance of the lesions, in decreasing order of frequency, is as follows:
    • Superficial erosion (50%)
    • Hyperpigmented macule or purpura (30-42%)
    • Excoriation (17%)
    • Deep necrosis, ulceration (17%)
    • Irritant dermatoses (17%)
    • Papules (17%)
    • Crusts (8%)
    • Scars - Pinpoint, star-shaped, atypically shaped (8%)
    • Onychodystrophy
    • Other - Keratosis, tattoolike
  • Usually, 72% of patients have one type of lesion morphology, 41% have 2 types of lesion morphology, and 31% have 3 types of lesion morphology.
  • In 66% of patients, involvement is limited to one body segment. In 34%, involvement is with 2 body segments.
  • Dermatitis artefacta must be distinguished from dermatitis neglecta, neurotic excoriations, trichotillomania, and painful bruise syndrome.

Causes

The cause is multifactorial. One should be sure to rule out hypochondriasis, substance abuse disorder, and psychotic disorders.

  • Genetic predisposition: Many psychiatric disorders tend to be familial.
  • Psychiatric illness: Associations include anxiety disorders, major depressive disorder, dysthymia, body dysmorphic disorder, factitious disorders, and somatoform disorders.
    • Neuropsychological trauma - Child abuse/neglect, sexual abuse, posttraumatic stress disorder
    • Personality disorders - Attention-seeking traits (eg, borderline, dependent), obsessions, compulsions
    • Psychosocial factors - Poor coping mechanisms, family dysfunction, inadequate social support structure
  • Chronic illnesses: These are commonly associated with dermatitis artefacta.
    • Dermatological disorders - Specifically, acne, alopecia (ie, alopecia areata, androgenic alopecia), atopic dermatitis, chronic idiopathic urticaria, psoriasis, rosacea, and vitiligo
    • Any long-standing medical illness
    • Chronic pain syndromes



Alopecia Areata
Anagen Effluvium
Atopic Dermatitis
Bedbug Bites
Contact Dermatitis, Allergic
Contact Dermatitis, Irritant
Delusions of Parasitosis
Friction Blisters
Impetigo
Insect Bites
Neurotic Excoriations
Onycholysis
Prurigo Nodularis
Pruritus and Systemic Disease
Telogen Effluvium
Trichotillomania

Other Problems to be Considered

Body dysmorphic disorder
Factitious disorder
Delusional disorder
Malingering
Münchhausen syndrome (by proxy)
Personality disorder - Borderline, dependent, obsessive-compulsive
Somatoform disorder



Lab Studies

  • No specific laboratory blood tests are required.

Imaging Studies

  • No imaging studies are required.

Other Tests

  • No other general tests are required.

Procedures

  • Skin biopsy is necessary.

Histologic Findings

A skin biopsy of a representative lesion may be performed to rule out any underlying pathology and, in some cases, to establish a definite diagnosis. The histologic findings in dermatitis artefacta are usually nonspecific and are often dependent on the mechanism of injury (eg, foreign body reaction with giant cells and noninfectious material for self-injection).



Medical Care

Dermatitis artefacta is a challenging condition that requires dermatologic and, often, psychiatric expertise.

  • General dermatological care measures include baths, debridement, emollients, and topical antimicrobials.
  • A detailed assessment of the patient history for chronic dermatoses, chronic medical conditions, psychiatric illnesses, and psychosocial problems is necessary.
  • An effective therapeutic relationship requires a nonjudgmental, empathetic, and supportive environment. Avoid etiology issues and confrontation. Developing a good rapport with the patient and encouraging the patient to return for follow-up appointments are important.
  • A psychiatric evaluation is warranted for severe self-mutilation and any evidence of psychiatric illness, psychosis, risk of suicide, and/or need for hospitalization.
  • Complementary adjuvant therapies may include acupuncture, cognitive behavioral therapy (ie, aversion therapy, systemic desensitization, operant conditioning), biofeedback and relaxation therapy (ie, anxiety-related dermatitis artefacta), and hypnosis.

Surgical Care

No surgical care is required.

Consultations

Consultation with a psychiatrist is recommended.



Topical antimicrobials are the most commonly prescribed medication; however, topical agents alone have shown limited efficacy. In many instances, treating the underlying psychiatric disorder with antidepressants, antianxiety drugs, and antipsychotic agents is necessary. Analgesics should be avoided because of the high probability for dependence and addiction.

Drug Category: Topical antimicrobials

Self-inflicted lesions are often accompanied by a localized skin infection.

Drug NameBacitracin, Neomycin and Polymyxin B (AK-Spore Ointment, Neocin, Neosporin)
DescriptionBacitracin prevents transfer of mucopeptides into growing cell wall, inhibiting bacterial growth.
Neomycin is used for treatment of minor infections; inhibits bacterial protein synthesis and growth. Polymyxin B disrupts bacterial cytoplasmic membrane, permitting leakage of intracellular constituents and causing inhibition of bacterial growth.
Adult DoseApply 1-4 times/d to affected areas and cover with sterile bandages prn
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; epithelial herpes simplex keratitis; mycobacterial and fungal infections
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution when treating extensive burns (>20% BSA) because absorption of neomycin is possible and may cause nephrotoxicity and ototoxicity; prolonged use may result in overgrowth of nonsusceptible organisms

Drug NameFusidic acid (Fucidin, Fusidin, Fusidin Leo)
DescriptionTopical antibacterial that inhibits bacterial protein synthesis, causing bacterial death.
Adult DoseApply to affected area bid for 2 wk
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDiscontinue if irritation or sensitivity occurs

Drug Category: Oral antibiotics

For impetiginized skin lesions.

Drug NameCephalexin (Keflex, Keftab, Biocef)
DescriptionFirst-generation cephalosporin that inhibits bacterial replication by inhibiting bacterial cell wall synthesis. Bactericidal and effective against rapidly growing organisms forming cell walls. Resistance occurs by alteration of penicillin-binding proteins. Effective for treatment of infections caused by streptococci or staphylococci, including penicillinase-producing staphylococci. May use to initiate therapy when streptococcal or staphylococcal infection is suspected. Used orally when outpatient management is indicated. Recommended for impetigo caused by Staphylococcus aureus resistant to erythromycin. Primary activity against skin florae. Used for skin infections or prophylaxis in minor procedures.
Adult Dose500 mg PO q6h for 10 d
Pediatric Dose25-50 mg/kg/d PO q6h for 10 d; not to exceed 3 g/d
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameErythromycin (E-Mycin, Eryc, Ery-Tab)
DescriptionUse with hypersensitivity or contraindication to penicillin or cephalexin. May result in GI upset, prompting prescription of an alternative macrolide or a change to tid dosing. Covers most potential etiologic agents, including Mycoplasma species.
Less active against Haemophilus influenzae. Although 10 d seems to be a standard course of treatment, treating until patient has been afebrile for 3-5 d seems more rational. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections.
In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half the total daily dose may be taken q12h. For more severe infections, double the dose. Has added advantage of being a good anti-inflammatory agent by inhibiting migration of polymorphonuclear leukocytes.
Adult Dose250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) PO q6h, or 500 mg q12h (1 h ac or 2 h pc)
Alternatively, 333 mg PO q8h; increase to 4 g/d depending on severity of infection
Pediatric Dose30-50 mg/kg/d (base or ethylsuccinate) PO divided q6-8h; not to exceed 2 g/d (base) or 3.2 g/d (ethylsuccinate)
ContraindicationsDocumented hypersensitivity; hepatic impairment
InteractionsCoadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis; decreases metabolism of repaglinide, thus increasing serum levels and effects
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsCaution in liver disease; estolate formulation may cause cholestatic jaundice; adverse GI effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occurs

Drug Category: Selective serotonin reuptake inhibitors

First-line therapy for depression. Other medications in this category include paroxetine, citalopram, and sertraline. For dermatitis artefacta associated with obsessive-compulsive disorder, the use of an SSRI for at least 6 months to 1 year accompanied by psychotherapy is recommended.

Drug NameFluoxetine (Prozac)
DescriptionSelectively inhibits presynaptic serotonin reuptake with minimal or no effect in reuptake of norepinephrine or dopamine.
May cause more adverse GI effects than other SSRIs currently available, which is the reason it is not recommended as a first choice. May be given as a liquid and a cap.
May give as single dose or in divided doses. Presence of food does not appreciably alter medication levels. May take up to 4-6 wk to achieve steady-state levels because of long half-life (72 h).
Long half-life is both an advantage and a drawback. If it works well, an occasional missed dose is not a problem; if problems occur, eliminating all active metabolites takes a long time. Choice depends on adverse effects and drug interactions. Adverse effects of SSRIs seem to be quite idiosyncratic; thus, if dosing is started at a conservative level and advanced as tolerated, relatively few reasons exist to recommend one over another.
Adult Dose20 mg/d PO in morning and increase after several wk by 20 mg/d; not to exceed 80 mg/d
Note: If patient is taking 20 mg/d, may initiate once-weekly dosing with 90-mg delayed-release product 7 d after last daily dose of 20 mg
Pediatric Dose<8 years: Not established
>8 years: 10-20 mg PO qd
ContraindicationsDocumented hypersensitivity; concurrently taking MAOIs or took them in last 2 wk; coadministration with thioridazine
InteractionsIncreases toxicity of diazepam and trazodone by decreasing clearance; also increases toxicity of MAOIs and highly protein-bound drugs; serotonin syndrome (ie, myoclonus, rigidity, confusion, nausea, hyperthermia, autonomic instability, coma, eventual death) occurs with simultaneous use of other serotonergic agents (eg, anorectic agents, tramadol, buspirone, trazodone, clomipramine, nefazodone, tryptophan); discontinue other serotonergic agents at least 2 wk prior to SSRI initiation
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsCaution in hepatic impairment and history of seizures; discontinue MAOIs at least 14 d before initiating therapy

Drug Category: Tricyclic antidepressants

Drug NameDoxepin (Sinequan, Zonalon)
DescriptionHas antihistamine, antipruritic, and antidepressant properties. May be effective for depression (with agitation) and a primary symptom of pruritus.
Increases concentration of serotonin and norepinephrine in CNS by inhibiting their reuptake by presynaptic neuronal membrane, which is associated with a decrease in symptoms of depression.
Adult Dose30-150 mg/d PO hs or 2-3 divided doses; gradually increase dose to 300 mg/d prn; maintain effective dose for at least 6-8 wk
Pediatric Dose<12 years: Not recommended
>12 years: 25-50 mg/d PO hs or bid/tid and increase gradually to 100 mg/d
ContraindicationsDocumented hypersensitivity; urinary retention; acute recovery phase following myocardial infarction; glaucoma
InteractionsDecreases antihypertensive effects of clonidine but increases effects of sympathomimetics and benzodiazepines; effects of desipramine increase with phenytoin, carbamazepine, and barbiturates
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in cardiovascular disease, conduction disturbances, seizure disorders, urinary retention, hyperthyroidism, and thyroid replacement therapy

Drug NameAmitriptyline (Elavil, Endep)
DescriptionMay be effective for depression with primary symptoms of pain sensations (eg, burning, chafing, stinging). Analgesia usually requires doses <50 mg qhs.
Inhibits reuptake of serotonin and/or norepinephrine at presynaptic neuronal membrane, which increases concentration in CNS. May increase or prolong neuronal activity because reuptake of these biogenic amines is important physiologically in terminating transmitting activity.
Adult Dose25-150 mg/d mg PO hs; use minimum effective dose
Pediatric DoseChildren: 0.1 mg/kg PO hs; increase as tolerated over 2-3 wk to 0.5-2 mg/d hs
Adolescents: 25-50 mg/d PO initially; increase gradually to 100 mg/d in divided doses
ContraindicationsDocumented hypersensitivity; use of MAOIs within 14 d of initiating therapy; history of seizures, cardiac arrhythmias, glaucoma, or urinary retention
InteractionsPhenobarbital may decrease effects; coadministration with CYP2D6 enzyme system inhibitors (eg, cimetidine, quinidine) may increase levels; inhibits hypotensive effects of guanethidine; may interact with thyroid medications, alcohol, CNS depressants, barbiturates, and disulfiram
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in cardiac conduction disturbances and history of hyperthyroidism, renal, impairment, or hepatic impairment; avoid use in elderly persons

Drug Category: Typical antipsychotics

Drug NamePimozide (Orap)
DescriptionPreviously shown to be effective for delusions of parasitosis. Centrally acting dopamine-receptor antagonist. Available in 2-mg scored tab in United States; 2-, 4-, and 10-mg tab available in Canada. Clinical response usually occurs within 10-14 d.
Adult Dose1-2 mg PO qd initially; increase by 2-4 mg at weekly intervals; not to exceed 10 mg/d or 200 mcg/kg/d (0.2 mg/kg/d); maintain effective therapeutic dose for at least 1 mo and then titrate down in 1-mg decrements over 1-2 wk until minimum effective dose is achieved
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; history of cardiac arrhythmias or long QT syndrome; concurrently with macrolide antibiotics
InteractionsIncreases toxicity of MAOIs, alfentanil, CNS depressants, and guanabenz
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsECG recommended at initiation of therapy and regular intervals thereafter; careful observation for appearance of extrapyramidal symptoms (eg, akathisia, rigidity, dystonia, irreversible tardive kinesia) necessary in geriatric patients; adverse effect of restlessness (akathisia) may be treated with diphenhydramine or benztropine

Drug Category: Atypical antipsychotics

Lower risk of extrapyramidal adverse effects than with typical antipsychotics.

Drug NameRisperidone (Risperdal)
DescriptionPreviously shown to be effective for delusions of parasitosis. Binds to dopamine D2 receptor with 20-times lower affinity than for 5-HT2 receptor. Improves negative symptoms of psychoses and reduces prevalence of extrapyramidal adverse effects. Indicated for treatment of psychotic disorders, including schizophrenia and bipolar disorder. Clinical response usually occurs within 10-14 d.
Adult Dose2-6 mg PO qhs; start at 0.5 or 1 qhs; may divide into bid dosing
Pediatric Dose<16 years: Not recommended
>16 years: 0.5-1 mg PO bid; not to exceed 6 mg/d
ContraindicationsDocumented hypersensitivity.
InteractionsCoadministration with carbamazepine may decrease effects; may inhibit effects of levodopa; clozapine may increase levels; oral solution not compatible with cola or tea
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay cause extrapyramidal reactions, hypotension, tachycardia, and arrhythmias; hyperglycemia may occur and, in some cases, be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; do not split or chew oral disintegrating tab

Drug NameOlanzapine (Zyprexa)
DescriptionMay inhibit serotonin, muscarinic, and dopamine effects. Efficacy similar to risperidone; has fewer dose-dependent adverse effects but is associated with more concern about weight gain.
Adult Dose5-20 mg/d PO in divided doses; lower doses recommended for dermatology-related psychoses
Pediatric DoseChildren: Not established
Adolescents: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsFluvoxamine may increase effects; antihypertensives may increase risk of hypotension and orthostatic hypotension; levodopa, pergolide, bromocriptine, charcoal, carbamazepine, omeprazole, rifampin, and cigarette smoking may decrease effects
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in narrow-angle glaucoma, cardiovascular disease, cerebrovascular disease, prostatic hypertrophy, seizure disorders, hypovolemia, and dehydration; hyperglycemia may occur and in some cases be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; administration of more than 1 IM injection is associated with substantial orthostatic hypotension (33%), thus, maintain patient in recumbent position and monitor blood pressure before repeating IM doses

Drug NameQuetiapine (Seroquel)
DescriptionMay act by antagonizing dopamine and serotonin effects. Efficacy similar to risperidone and olanzapine. Fewer dose-dependent adverse effects and less concern for weight gain.
Adult Dose25 mg PO bid; titrate to 150-750 mg/d PO; not to exceed 800 mg/d; lower doses recommended for dermatology-related psychoses
Pediatric DoseChildren: Not established
Adolescents: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsMay antagonize levodopa and dopamine agonists; phenytoin, thioridazine, and other liver enzyme inducers may reduce levels; CYP4503A inhibitors (eg, ketoconazole, fluconazole, erythromycin) increase serum concentrations
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsMay induce orthostatic hypotension associated with dizziness, tachycardia, and syncope; neuroleptic malignant syndrome and tardive dyskinesia have been associated with this treatment; hyperglycemia may occur and, in some cases, be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; caution in hepatic impairment (decrease dose)



Further Inpatient Care

  • Hospitalization may be required depending on the severity of the skin lesions and the risk of suicide.

Further Outpatient Care

  • Frequent follow-up visits with a dermatologist and/or psychiatrist are recommended.
  • Note that many dermatitis artefacta patients are often lost to follow-up.
  • With Münchhausen syndrome by proxy, removal of the child to a safe environment is mandatory.

In/Out Patient Meds

  • Selective serotonin reuptake inhibitors (eg, paroxetine, sertraline, citalopram, fluoxetine) are first-line therapy for depression.
  • A tricyclic antidepressant with antihistamine, antipruritic, and antidepressant properties (eg, doxepin) is recommended for depression with or without agitation and the primary symptom of pruritus.
  • A tricyclic antidepressant with analgesic properties (eg, amitriptyline) is appropriate for depression with a primary symptom of pain sensations (eg, burning, chafing, stinging).
  • Typical (eg, pimozide) and atypical antipsychotics (eg, risperidone, olanzapine, quetiapine) are for short-term use, particularly if skin lesions are associated with psychotic or delusional symptoms.

Prognosis

  • Mild cases secondary to identifiable psychosocial stressors usually have a good outcome; cure is possible.
  • Chronic cases with associated chronic dermatological or medical issues usually have a poor outcome, and cure is usually not possible.

Patient Education

  • The unique presentation and appearance of skin lesions may be a cause of significant concern to the patient and the parents or caregivers.
  • Avoid confrontational issues regarding the etiology of lesions during initial patient visits.
  • Gradually introduce the role of psychosocial factors and/or psychiatric issues that may contribute to the self-inflicted skin lesions.
  • Regularly assess the risk of self-harm (suicide) or harm towards others.



Medical/Legal Pitfalls

  • Identify any risk factors for suicide and a need for hospitalization, as well as the potential for harm to others.
  • In cases of Münchhausen syndrome by proxy, the victim (usually a child younger than 5 y) must be removed from the offender (usually a female caregiver or the mother) and placed in a safe, protected environment.



  • Angus J, Affleck AG, Croft JC, Leach IH, Slater DN, Millard LG. Dermatitis artefacta in a 12-year-old girl mimicking cutaneous T-cell lymphoma. Pediatr Dermatol. May-Jun 2007;24(3):327-9. [Medline].
  • Cohen AD, Vardy DA. Dermatitis artefacta in soldiers. Mil Med. Jun 2006;171(6):497-9. [Medline].
  • Fabisch W. What is dermatitis artefacta?. Int J Dermatol. Jul-Aug 1981;20(6):427-8. [Medline].
  • Gupta MA, Gupta AK, Ellis CNl, Koblenzer CS. Psychiatric evaluation of the dermatology patient. Dermatol Clin. Oct 2005;23(4):591-9. [Medline].
  • Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. Nov 2001;15(6):512-8. [Medline].
  • Harries MJ, McMullen E, Griffiths CE. Pyoderma gangrenosum masquerading as dermatitis artefacta. Arch Dermatol. Nov 2006;142(11):1509-10. [Medline].
  • Joe EK, Li VW, Magro CM, Arndt KA, Bowers KE. Diagnostic clues to dermatitis artefacta. Cutis. Apr 1999;63(4):209-14. [Medline].
  • Koblenzer CS. Dermatitis artefacta. Clinical features and approaches to treatment. Am J Clin Dermatol. Jan-Feb 2000;1(1):47-55. [Medline].
  • Lee CS, Koo J. Psychopharmacologic therapies in dermatology: an update. Dermatol Clin. Oct 2005;23(4):735-44. [Medline].
  • Ozmen M, Erdogan A, Aydemir EH, Oguz O. Dissociative identity disorder presenting as dermatitis artefacta. Int J Dermatol. Jun 2006;45(6):770-1. [Medline].
  • Saez-de-Ocariz M, Orozco-Covarrubias L, Mora-Magana I, et al. Dermatitis artefacta in pediatric patients: experience at the national instituteof pediatrics. Pediatr Dermatol. May-Jun 2004;21(3):205-11. [Medline].
  • Shah KN, Fried RG. Factitial dermatoses in children. Curr Opin Pediatr. Aug 2006;18(4):403-9. [Medline].
  • Shenefelt PD. Complementary psychocutaneous therapies in dermatology. Dermatol Clin. Oct 2005;23(4):723-34. [Medline].
  • Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatol Clin. Oct 2005;23(4):601-8. [Medline].

Dermatitis Artefacta excerpt

Article Last Updated: Aug 24, 2007